Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan(University of California, San Francisco), Matthew R. Smith(Harvard University), Karim Fizazi(Université Paris-Sud), Fred Saad(Université de Montréal), Peter F.A. Mulders(Radboud University Nijmegen), Cora N. Sternberg(Carlo Forlanini Hospital), Kurt Miller(Charité - Universitätsmedizin Berlin), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Neal D. Shore(Carolina Urologic Research Center), Eric J. Small(University of California, San Francisco), Joan Carles(Hebron University), Thomas W. Flaig(University of Colorado Cancer Center), Mary-Ellen Taplin(Harvard University), Celestia S. Higano(University of Washington), Paul de Souza(Ingham Institute), Johann S. de Bono(Institute of Cancer Research), Thomas W. Griffin(Janssen (Belgium)), Peter De Porre(Janssen (Belgium)), Margaret K. Yu(Janssen (Belgium)), Youn C. Park(Janssen (United States)), Jinhui Li(Janssen (United States)), Thian Kheoh(Janssen (Belgium)), Vahid Naini(Janssen (Belgium)), Arturo Molina(Menlo School), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center)
Cited by 1,346
Abstract
Related Papers
No related papers found
Powered by citation graph analysis